Bristol Myers Squibb Company $BMY Shares Sold by Contravisory Investment Management Inc.

Key Points

• Contravisory Investment Management cut its stake in Bristol Myers Squibb by 97.8% in Q3, selling 133,173 shares and leaving just 2,954 shares valued at about $133,000.
• Bristol Myers reached an agreement with the U.S. government on drug affordability as part of voluntary pricing deals by nine pharma firms, a move that reduces regulatory uncertainty but could create longer‑term pricing pressure.
• The company showed pipeline momentum with BioNTech collaboration and mixed analyst views (average rating: Hold, target ~$54.62), while also raising its quarterly dividend to $0.63—about a 4.7% yield.

Contravisory Investment Management Inc. reduced its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 97.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,954 shares of the biopharmaceutical company's stock after selling 133,173 shares during the period. Contravisory Investment Management Inc.'s holdings in Bristol Myers Squibb were worth $133,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. New England Asset Management Inc. boosted its holdings in Bristol Myers Squibb by 0.8% in the first quarter. New England Asset Management Inc. now owns 39,476 shares of the biopharmaceutical company's stock valued at $2,408,000 after purchasing an additional 305 shares during the last quarter. Commonwealth Retirement Investments LLC lifted its holdings in shares of Bristol Myers Squibb by 24.6% in the 2nd quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company's stock valued at $2,740,000 after buying an additional 11,690 shares during the period. Norges Bank purchased a new stake in shares of Bristol Myers Squibb in the second quarter worth about $1,554,154,000. Wealth Quarterback LLC grew its holdings in Bristol Myers Squibb by 42.6% during the second quarter. Wealth Quarterback LLC now owns 25,443 shares of the biopharmaceutical company's stock worth $1,178,000 after acquiring an additional 7,603 shares during the period. Finally, Sound View Wealth Advisors Group LLC raised its position in Bristol Myers Squibb by 438.0% during the second quarter. Sound View Wealth Advisors Group LLC now owns 307,849 shares of the biopharmaceutical company's stock valued at $14,250,000 after acquiring an additional 250,624 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers publicly announced an agreement with the U.S. government to improve affordability and access to medicines — a company release that frames the deal as preserving market access while responding to pricing pressures. This reduces regulatory uncertainty and the risk of punitive measures that could have hurt sales. Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
• Positive Sentiment: BMY and partner BioNTech reported progress in immunotherapy clinical programs (first-line liver cancer and a kidney‑cancer trial update), which add long-term commercial optionality if late‑stage data confirms benefit. These pipeline moves support upside beyond near‑term pricing headwinds. New Pumitamig Kidney Cancer Trial Adds Long-Term Optionality for Bristol-Myers Squibb and BioNTech
• Positive Sentiment: Analyst and media endorsements are visible: Guggenheim raised/maintained an elevated price target after an FDA priority review and media commentators (including Jim Cramer) are calling BMY a buy/value name — these signals can attract momentum and retail/institutional buyers. Guggenheim sets $62 target on Bristol-Myers Squibb Company (BMY) after FDA priority review
• Neutral Sentiment: Major press outlets report that nine pharma companies (including BMY) struck voluntary price agreements with the White House to link some U.S. prices to lower foreign prices and to avoid potential tariffs — this offers regulatory clarity but also implies longer‑term pricing pressure. Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
• Neutral Sentiment: Broader coverage (CNBC) confirms multiple large drugmakers are making similar deals with the administration — increases industry momentum toward pricing reforms but spreads the competitive/market impact across peers. Nine of the largest pharma companies ink deals with Trump to lower drug prices
• Neutral Sentiment: BMY set a Q4 2025 earnings release date (Feb. 5, 2026) — a near‑term catalyst investors will watch for sales impact from pricing agreements and pipeline progress. Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
• Negative Sentiment: Analyst model updates from Zacks Research trimmed several near‑term EPS estimates and cut FY2027 estimates modestly, implying some downward revision risk to earnings expectations if pricing concessions or volume shifts persist. (Zacks research notes summarized across recent releases.)
• Positive Sentiment: Market commentary pieces positioning BMY as a long‑term value stock may attract defensive/value investors given the company's dividend/cash flow profile and pipeline depth. Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

Wall Street Analysts Forecast Growth

BMY has been the topic of a number of analyst reports. Dbs Bank raised shares of Bristol Myers Squibb to a "moderate buy" rating in a research note on Thursday, October 2nd. Morgan Stanley reissued an "underweight" rating and set a $37.00 price target (up from $36.00) on shares of Bristol Myers Squibb in a report on Friday, December 12th. Bank of America raised shares of Bristol Myers Squibb from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $52.00 to $61.00 in a report on Monday, December 15th. HSBC reissued a "hold" rating and set a $53.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Finally, Wells Fargo & Company lifted their price target on Bristol Myers Squibb from $53.00 to $55.00 and gave the company an "equal weight" rating in a research note on Wednesday, December 10th. Five equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Bristol Myers Squibb currently has an average rating of "Hold" and an average target price of $54.62.

Bristol Myers Squibb Stock Performance

BMY opened at $54.15 on Friday. The firm's fifty day simple moving average is $47.73 and its two-hundred day simple moving average is $47.15. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $63.33. The company has a market cap of $110.24 billion, a price-to-earnings ratio of 18.29, a PEG ratio of 8.16 and a beta of 0.29. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The firm had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.75 billion. During the same quarter in the prior year, the firm earned $1.80 EPS. The company's revenue for the quarter was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be given a dividend of $0.63 per share. The ex-dividend date is Friday, January 2nd. This is a positive change from Bristol Myers Squibb's previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a dividend yield of 4.7%. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 83.78%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.